BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35587532)

  • 1. Systemic Immune Dysfunction in Cancer Patients Driven by IL6 Induction of LAG3 in Peripheral CD8+ T Cells.
    Somasundaram A; Cillo AR; Lampenfeld C; Workman CJ; Kunning S; Oliveri L; Velez M; Joyce S; Calderon M; Dadey R; Rajasundaram D; Normolle DP; Watkins SC; Herman JG; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Vignali DAA
    Cancer Immunol Res; 2022 Jul; 10(7):885-899. PubMed ID: 35587532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association Between Expression Level of PD1 by Tumor-Infiltrating CD8
    Kim HD; Song GW; Park S; Jung MK; Kim MH; Kang HJ; Yoo C; Yi K; Kim KH; Eo S; Moon DB; Hong SM; Ju YS; Shin EC; Hwang S; Park SH
    Gastroenterology; 2018 Dec; 155(6):1936-1950.e17. PubMed ID: 30145359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding.
    Andrews LP; Somasundaram A; Moskovitz JM; Szymczak-Workman AL; Liu C; Cillo AR; Lin H; Normolle DP; Moynihan KD; Taniuchi I; Irvine DJ; Kirkwood JM; Lipson EJ; Ferris RL; Bruno TC; Workman CJ; Vignali DAA
    Sci Immunol; 2020 Jul; 5(49):. PubMed ID: 32680952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor.
    Ruffo E; Wu RC; Bruno TC; Workman CJ; Vignali DAA
    Semin Immunol; 2019 Apr; 42():101305. PubMed ID: 31604537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG3 and PD1 Regulate CD8+ T Cell in Diffuse Large B-cell Lymphoma Patients.
    Liu Y; Guo X; Zhan L; Wang L; Wang X; Jiang M
    Comput Math Methods Med; 2021; 2021():4468140. PubMed ID: 34422089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
    Huang RY; Eppolito C; Lele S; Shrikant P; Matsuzaki J; Odunsi K
    Oncotarget; 2015 Sep; 6(29):27359-77. PubMed ID: 26318293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
    Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
    Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LAG3 (CD223) as a cancer immunotherapy target.
    Andrews LP; Marciscano AE; Drake CG; Vignali DA
    Immunol Rev; 2017 Mar; 276(1):80-96. PubMed ID: 28258692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function and regulation of LAG3 on CD4
    Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
    Exp Cell Res; 2017 Nov; 360(2):358-364. PubMed ID: 28935468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Pathways and Mechanisms of LAG3 in Cancer Therapy.
    Andrews LP; Cillo AR; Karapetyan L; Kirkwood JM; Workman CJ; Vignali DAA
    Clin Cancer Res; 2022 Dec; 28(23):5030-5039. PubMed ID: 35579997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3.
    Lauder SN; Smart K; Kersemans V; Allen D; Scott J; Pires A; Milutinovic S; Somerville M; Smart S; Kinchesh P; Lopez-Guadamillas E; Hughes E; Jones E; Scurr M; Godkin A; Friedman LS; Vanhaesebroeck B; Gallimore A
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33093155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progesterone receptor impairs immune respond and down-regulates sensitivity to anti-LAG3 in breast cancer.
    Xiao Y; Zheng P; Xu W; Wu Z; Zhang X; Wang R; Huang T; Ming J
    Transl Res; 2024 Sep; 271():68-78. PubMed ID: 38795691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple Myeloma.
    Lucas F; Pennell M; Huang Y; Benson DM; Efebera YA; Chaudhry M; Hughes T; Woyach JA; Byrd JC; Zhang S; Jones D; Guan X; Burd CE; Rosko AE
    Biol Blood Marrow Transplant; 2020 Jan; 26(1):7-15. PubMed ID: 31445183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunologic Features of Patients With Advanced Hepatocellular Carcinoma Before and During Sorafenib or Anti-programmed Death-1/Programmed Death-L1 Treatment.
    Macek Jilkova Z; Aspord C; Kurma K; Granon A; Sengel C; Sturm N; Marche PN; Decaens T
    Clin Transl Gastroenterol; 2019 Jul; 10(7):e00058. PubMed ID: 31295151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
    Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LAG3 (CD223) and autoimmunity: Emerging evidence.
    Hu S; Liu X; Li T; Li Z; Hu F
    J Autoimmun; 2020 Aug; 112():102504. PubMed ID: 32576412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphocyte activation gene 3 (LAG3) protein expression on tumor-infiltrating lymphocytes in aggressive and TP53-mutated salivary gland carcinomas.
    Arolt C; Meyer M; Ruesseler V; Nachtsheim L; Wuerdemann N; Dreyer T; Gattenlöhner S; Wittekindt C; Buettner R; Quaas A; Klussmann JP
    Cancer Immunol Immunother; 2020 Jul; 69(7):1363-1373. PubMed ID: 32232506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased LAG3 expression on T effector cells and regulatory T cells in SAA.
    Sun Y; Liu C; Jiao T; Xie N; Wang H; Qi W; Shao Z
    Int J Hematol; 2020 Dec; 112(6):757-763. PubMed ID: 32785818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.